Xponance, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
Xponance, Inc.
- $10.2 Billion
- Q3 2024
A detailed history of Xponance, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 5,116 shares of CRNX stock, worth $286,854. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,116
Previous 4,930
3.77%
Holding current value
$286,854
Previous $220,000
18.64%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$353 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$349 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$330 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$277 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$250 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $3.01B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...